Plain-English translation of NCT06182774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with multiple myeloma who are not candidates for stem cell transplant can safely stop receiving or (injectable medications) after completing about 18-20 cycles of initial treatment, while continuing to take their oral pills. The standard approach is to keep taking these injections indefinitely, but researchers want to know if stopping the injections—while staying on the oral medications—works just as well and might reduce side effects.
Currently, patients receive this medication continuously for as long as it keeps working, which can mean years of ongoing injections. This trial exists to see whether a shorter, fixed course of the injectable medication followed by oral-only treatment could be equally effective while potentially reducing the burden of frequent injections and associated side effects.
You likely qualify if…
You likely don't qualify if…
After completing your initial 18-20 cycles of treatment, you will be randomly assigned to either continue all your current medications (the standard group) or stop the injectable medication and continue only your oral pills (the experimental group). You will continue whichever treatment you are assigned to as long as it is helping you and you tolerate it well. You will need to attend regular clinic visits for blood tests, disease monitoring, and check-ins with your care team, and complete questionnaires about how you are feeling.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Canada